Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148821 | 1.00 | CA2 (0.36) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| Hydrochloric Acid SCHEMBL837997 | 0.97 | CA2 (0.35) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL27829241 | 0.80 | CA2 (0.34) | CA2ALDH1A1MAPTPTGS1 | |
| SCHEMBL7756606 | 0.77 | CNR2 (0.31) | — | |
| SCHEMBL13967018 | 0.77 | L3MBTL1 (0.30) | — | |
| SCHEMBL16501774 | 0.77 | L3MBTL1 (0.30) | — | |
| SCHEMBL7270355 | 0.77 | CYP2B6 (0.34) | CA2 | |
| SCHEMBL3458098 | 0.76 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL28479550 | 0.76 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 | |
| SCHEMBL3458099 | 0.76 | CA2 (0.37) | CA2ALDH1A1MAPTPTGS1SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260535-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2022-12-15 | — | — | WO | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-9040566-B2 | Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-05-26 | — | — | US | disclosed |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER IP GMBH (DE) | 2015-05-14 | — | — | US | disclosed |
| US-8957017-B2 | Dipeptoid prodrugs and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-02-17 | — | — | US | disclosed |
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-07-24 | — | — | US | disclosed |
| US-8741834-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-03 | — | — | US | disclosed |
| US-8703696-B2 | Dipeptoid prodrugs and the use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-22 | — | — | US | disclosed |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT | 2011-12-01 | — | — | US | disclosed |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | Bayer Schering Pharma | 2011-12-01 | — | — | US | disclosed |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206879-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | CA2 1318/4885ALDH1A1 619/4885MAPT 3531/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CA2 257/4885ALDH1A1 3628/4885MAPT 1956/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | CA2 4756/4885ALDH1A1 2249/4885MAPT 1536/4885 |
| US-20110294719-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DNPEP | CA2 1601/4885ALDH1A1 1237/4885MAPT 4536/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | CA2 209/4885ALDH1A1 4627/4885MAPT 1123/4885 |
| US-20110294718-A1 | DIPEPTOID PRODRUGS AND THE USE THEREOF | DPP4, DPP3, DPP7 | CA2 1582/4885ALDH1A1 579/4885MAPT 3949/4885 |
| US-20110237629-A1 | AMINO ACID ESTER PRODRUGS AND THE USE THEREOF | DNPEP, AADAT, DAO | CA2 1422/4885ALDH1A1 1058/4885MAPT 4371/4885 |
| US-20150133364-A1 | DIPEPTOID PRODRUGS AND THEIR USE | DPP4, DPP3, DPP7 | CA2 1318/4885ALDH1A1 619/4885MAPT 3531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.